Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimexolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 10/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.61 |
| ▸ | AR | P10275 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL6 | P05231 | 1/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.61 |
| ▸ | GLUL | P15104 | 1/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimexolone SCHEMBL3062722 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030108 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL29030109 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL1651214 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL13693339 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1ALMNANR1I2 | |
| Rimexolone SCHEMBL19327140 | 0.94 | NR3C1 (0.88) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470879 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9470890 | 0.92 | NR3C1 (0.86) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9467046 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ALMNANR1I2 | |
| SCHEMBL9467031 | 0.91 | NR3C1 (0.84) | NR3C1PGRHIF1ALMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 922 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301343-B1 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED SIDE EFFECT AND METHODS OF USING THE SAME | TLC BIOPHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | claimed |
| EP-4616867-A1 | COMBINATION OF ENDOTHELIN RECEPTOR ANTAGONIST AND GLUCOCORTICOID FOR TREATING IGA NEPHROPATHY | Sanreno Therapeutics (Shanghai) Limited (CN) | 2025-09-17 | — | — | EP | claimed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | claimed |
| EP-3943073-B1 | BIODEGRADABLE POLYMER MICROPARTICLE CONTAINING STEROID-BASED DRUG AND PREPARATION METHOD THEREFOR | REGENBIOTECH INC (KR) | 2025-03-26 | — | — | EP | claimed |
| EP-3496680-B1 | DEVICE FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL INC (US) | 2024-10-02 | — | — | EP | claimed |
| EP-3756665-B1 | INTERVAL THERAPY FOR THE TREATMENT OF EYE DISEASES | UNIV RAMOT (IL) | 2024-08-14 | — | — | EP | claimed |
| EP-3466408-B1 | LIQUID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A POSTERIOR EYE DISEASE | NOVALIQ GMBH (DE) | 2024-07-31 | — | — | EP | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4298219-A1 | TREATMENT OF INFLAMMATION WITH GLUCOCORTICOIDS AND ANGIOPOIETIN-LIKE 7 (ANGPTL7) INHIBITORS | Regeneron Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| EP-2054049-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2009-05-06 | — | — | EP | claimed |
| EP-2038252-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2008127717-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080076828-A1 | Substituted acylanilides and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-27 | — | — | US | claimed |
| US-20080076829-A1 | Substituted acylanilides and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-27 | — | — | US | claimed |
| US-20080057068-A1 | SARMS and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-06 | — | — | US | claimed |
| WO-2008024456-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008008433-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | claimed |
| US-20070281906-A1 | Selective androgen receptor modulators for treating diabetes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-12-06 | — | — | US | claimed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076829-A1 | Substituted acylanilides and methods of use thereof | CPT1B, MTPN, MUSK | NR3C1 1691/4885PGR 4383/4885HIF1A 600/4885 |
| US-20080057068-A1 | SARMS and method of use thereof | SARM1, CKMT1A; CKMT1B, TNNI3 | NR3C1 1811/4885PGR 4797/4885HIF1A 96/4885 |
| US-20070281906-A1 | Selective androgen receptor modulators for treating diabetes | AR, GPR119, NR5A1 | NR3C1 121/4885PGR 452/4885HIF1A 193/4885 |
| US-20080076828-A1 | Substituted acylanilides and methods of use thereof | CPT1B, MTPN, MUSK | NR3C1 1392/4885PGR 4105/4885HIF1A 1221/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885PGR 965/4885HIF1A 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.